

You're invited to an upcoming educational program

This is a promotional program sponsored by Johnson & Johnson; the speaker will be compensated.

Helping Close the Evidence Gap in Adjunctive MDD Treatment: A Network Meta-Analysis Review

Why attend? In this program the speaker will...

- Explore how network meta-analyses evaluating all FDA-approved adjunctive treatment options for adults with MDD may provide additional context in the absence of head-to-head clinical trials
- Discuss practical considerations for interpreting efficacy, safety, and tolerability findings across studies evaluating adjunctive treatment options for adults with MDD
- Review key data indirectly comparing CAPLYTA + ADT vs placebo + ADT with other atypical antipsychotics approved as adjunctive treatment options for aMDD

Program Details

Wednesday, October 28, 2026
6:15 PM Eastern Time
RusTeak Ocoee
1681 Amazing Way
Ocoee, FL, 34761

Richard Vowles, PMHNP-BC
PMHNP-NP
Psychiatry
Jacksonville, FL



Register today!

You can register by visiting
<https://www.itcpsychcenter.com?code=3ece3938-7ffe-45ba-874b-2cbc415ca5f4>
or by scanning the QR code.*

*Data rates may apply.

Johnson & Johnson's Policies

- Attendees may not include employees of the speaker's own medical practice (same physical location) or staff of facilities for which the speaker is a medical director (whose job function it is to educate those within their supervisory authority)
- An individual must not attend a Speaker Program on the same topic more than 2 times in a 12-month period



Not available? Check out the **Psych Center**
for more programs that may fit your schedule

ADT, antidepressant; FDA, U.S. Food and Drug Administration; MDD, major depressive disorder; NMA, network meta-analysis.

INDICATIONS

CAPLYTA® (lumateperone) is indicated in adults for adjunctive therapy along with antidepressants for the treatment of major depressive disorder (MDD); the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate; and the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION

BOXED WARNINGS:

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA® is not approved for the treatment of patients with dementia-related psychosis.
- Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA® have not been established in pediatric patients.

Please see additional Important Safety Information on the following page.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS: CAPLYTA® (lumateperone) is contraindicated in patients with a history of hypersensitivity to lumateperone or any components of CAPLYTA®. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria.

WARNINGS & PRECAUTIONS: Antipsychotic drugs have been reported to cause:

- **Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis**, including stroke and transient ischemic attack. See Boxed WARNING on the previous page.
- **Neuroleptic Malignant Syndrome**, which is a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA® and provide intensive symptomatic treatment and monitoring.
- **Tardive Dyskinesia (TD)** may develop in patients treated with antipsychotic drugs, including CAPLYTA®. TD can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. The TD risk appears to be highest in elderly women. The likelihood that TD will become irreversible increases with the duration of the antipsychotic drug treatment and cumulative dose. If signs and symptoms of TD appear, consider discontinuing CAPLYTA® if clinically appropriate.
- **Metabolic Changes**, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA® and monitor periodically during long-term treatment.
- **Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases)**. Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing CAPLYTA® if clinically significant decline in WBC occurs in absence of other causative factors. Discontinue CAPLYTA® in patients with clinically significant neutropenia or absolute neutrophil count <1000/mm³ and monitor closely until neutropenia resolves.
- **Orthostatic Hypotension and Syncope**. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.
- **Falls**. CAPLYTA® may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for fall risk when initiating treatment and periodically during long-term treatment.
- **Seizures**. Use CAPLYTA® cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
- **Potential for Cognitive and Motor Impairment**. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA® affects them.
- **Body Temperature Dysregulation**. Use CAPLYTA® with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.
- **Dysphagia**. Use CAPLYTA® with caution in patients at risk for aspiration.

DRUG INTERACTIONS:

- Avoid concomitant use with CYP3A4 inducers.
- Reduce dose for concomitant use with strong CYP3A4 inhibitors (10.5 mg) or moderate CYP3A4 inhibitors (21 mg).
- Increased monitoring for serotonin reuptake inhibitor (SSRI)-associated adverse reactions is recommended when used with SRIs; including in geriatric patients who may be at greater risk for clinically significant hyponatremia.

SPECIAL POPULATIONS: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Reduce dose for patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment (21 mg).

ADVERSE REACTIONS: The most common adverse reactions in clinical trials (≥5% and greater than twice placebo) with CAPLYTA® vs placebo were:

- Major Depressive Disorder (Adjunctive therapy): dizziness (17% vs 5%), dry mouth (13% vs 3%), somnolence/sedation (12% vs 2%), nausea (9% vs 4%), fatigue (8% vs 2%), and diarrhea (5% vs 1%).
- Bipolar Depression (Monotherapy, Adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%).
- Schizophrenia: somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%).

CAPLYTA® is available in 42 mg, 21 mg, and 10.5 mg capsules.

cp-548759v1

Please see accompanying full Prescribing Information, including Boxed WARNINGS for CAPLYTA®.

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company
1125 Trenton-Harbourton Road
Titusville, NJ 08560

© Johnson & Johnson and its affiliates 2026

08/26 cp-595495v1

Johnson & Johnson